European Association for Haematopathology 21st Meeting 2022

few years, triggered by the new DNA sequencing technologies and other molecular techniques that allow us to investigate the pathogenesis of well-known diseases as well as to recognize new emerging entities. We, as pathologists, need to integrate this new information with our solid morphologic background, which continues to be the essence of our profession. These innovative technologies have clinical impact, prompting the development of new targeted drugs and better therapeutic strategies for our patients. To bridge the gap, we have prepared an exciting programme devoted to “Novel frontiers in molecular diagnosis of lymphoma and myeloid neoplasms: biomarkers and integrative prognostic models”.

The goal is to explore how best to integrate into our daily clinical practice the plethora of new technologies that help us understand lymphoma biology and myeloid neoplasms. The highlight of our meeting is the Karl Lennert’s lecture, with which the EAHP honors an outstanding haematopathologist/biologist for their inspiring contribution in advancing and shaping the understanding of our field. The 2022 Karl Lennert awardee is Prof. Philippe Gaulard, a very esteemed past president of our Society, who will share with us his long adventure “Understanding peripheral T-cell lymphomas – lesson from the past moving to the future”. It is also with great pleasure that I announce the David Y Mason lecture, which is dedicated to honor the innovative approach to science and spirit of David Y Mason, who once said, “each technological advance applied in Pathology opens a window to a new landscape of knowledge”. This year we welcome Teresa Palomero with the lecture on “Oncogenic mechanisms in the development of T-cell lymphomas”. I also want to thank the generous contribution of the David Y Mason foundation and Teresa Marafioti for the Mason ́s Award that is given to a young researcher to foster interest in hematopathology. An important part of our meeting is the EAHP educational session. For this meeting, we have prepared a special long session dedicated to cover the two proposals to update the lymphoma and myeloid classifications. There have been 4 recent publications presenting the two classifications; the International Consensus Classification (2022 ICC), published in Blood, and the 5th Edition WHO classification, published in Leukemia. Certainly, our members and in general the hematopathology community will have questions on how to handle the practical reality of navigating these two classifications in their daily diagnostic work. Although many entities are identical in the two classifications, there are significant differences in nomenclature and diagnostic criteria for others, and some disease entities are recognized in one but not in both classifications. The educational session will be dedicated to present both classifications and try to highlight and discuss the different approaches. The session includes one hour at the end of the presentations for questions, to help our members to develop a roadmap to navigate specific diagnostic settings.